Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 868

1.

Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials.

Bała M, Sahebkar A, Ursoniu S, Serban MC, Undas A, Mikhailidis DP, Lip GYH, Rysz J, Banach M; Lipid Blood Pressure Meta-Analysis Collaboration Group.

Pharmacol Res. 2017 Oct;124:64-73. doi: 10.1016/j.phrs.2017.07.024. Epub 2017 Jul 29. Review.

PMID:
28760491
2.

Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer.

Whicker M, Black J, Altwerger G, Menderes G, Feinberg J, Ratner E.

Am J Obstet Gynecol. 2017 Oct;217(4):395-403. doi: 10.1016/j.ajog.2017.04.012. Epub 2017 Apr 12. Review.

PMID:
28411144
3.

The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis.

Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, Theodorou M, Goulis DG.

Maturitas. 2017 May;99:27-36. doi: 10.1016/j.maturitas.2017.02.009. Epub 2017 Feb 16. Review.

4.

Effects of Tibolone on the Central Nervous System: Clinical and Experimental Approaches.

Pinto-Almazán R, Segura-Uribe JJ, Farfán-García ED, Guerra-Araiza C.

Biomed Res Int. 2017;2017:8630764. doi: 10.1155/2017/8630764. Epub 2017 Jan 16. Review.

5.

Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women.

Vitale C, Mammi C, Gambacciani M, Russo N, Spoletini I, Fini M, Volterrani M, Rosano GMC.

Int J Cardiol. 2017 Jan 15;227:217-221. doi: 10.1016/j.ijcard.2016.11.149. Epub 2016 Nov 9.

PMID:
27843051
6.

Short-term and long-term effects of tibolone in postmenopausal women.

Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D'Amico R, Bassi C, Maestri E.

Cochrane Database Syst Rev. 2016 Oct 12;10:CD008536. Review.

PMID:
27733017
7.

A case of perimenopausal depression.

Worsley A, Smythe J, Kulkarni J.

Aust N Z J Psychiatry. 2016 Nov;50(11):1109. Epub 2016 Oct 3. No abstract available.

PMID:
27698111
8.

Postmenopausal Hormone Therapy and Breast Cancer Prognostic Characteristics: A Linkage between Nationwide Registries.

Román M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, Ursin G.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1464-1473. Epub 2016 Jul 26.

9.

[Utilization of hormone replacement therapy in Spain: Trends in the period 2000-2014].

Baladé Martínez L, Montero Corominas D, Macías Saint-Gerons D.

Med Clin (Barc). 2016 Oct 7;147(7):287-92. doi: 10.1016/j.medcli.2016.05.023. Epub 2016 Aug 8. Spanish.

PMID:
27423654
10.

Tibolone treatment for perimenopausal depression: Three cases.

Khan N, Gavrilidis E, Kulkarni J.

Aust N Z J Psychiatry. 2016 Dec;50(12):1213-1214. Epub 2016 Jun 29. No abstract available.

PMID:
27357711
11.

Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression.

Avila-Rodriguez M, Garcia-Segura LM, Hidalgo-Lanussa O, Baez E, Gonzalez J, Barreto GE.

Mol Cell Endocrinol. 2016 Sep 15;433:35-46. doi: 10.1016/j.mce.2016.05.024. Epub 2016 May 29.

PMID:
27250720
12.

Short-term tibolone does not interfere with endothelial function: a double-blinded, randomized, controlled trial.

Celani MF, Hurtado R, Brandão AH, Maciel da Fonseca AM, Geber S.

Climacteric. 2016 Jun;19(3):299-302. doi: 10.3109/13697137.2016.1159671. Epub 2016 Mar 31.

PMID:
27031181
13.

Use of hormone therapy and isoflavones and mammographic density in Spain.

Isidoro B, Lope V, Whelan D, Pedraz C, Sánchez-Contador C, Santamariña C, Moreo P, Vidal C, Salas-Trejo D, Ederra M, Aragonés N, Pérez-Gómez B, Pollán M.

Menopause. 2016 May;23(5):556-64. doi: 10.1097/GME.0000000000000569.

PMID:
26731688
14.

[Clinical and metabolic effects of drospirenone-estradiol versus tibolone in postmenopausal women:a comparative study].

Cheng J, Zhang Z.

Zhonghua Yi Xue Za Zhi. 2015 Jun 16;95(23):1815-8. Chinese.

PMID:
26712397
15.

Effects of low dose of tibolone on steroid receptors and Bcl-2 on the postmenopausal endometrium.

Reis BF, Lima SM, Silva GM, Francisco AM, Barbosa LC, Archangelo SC, Grande RM.

Histol Histopathol. 2016 Jun;31(6):629-34. doi: 10.14670/HH-11-706. Epub 2015 Dec 16.

PMID:
26670665
16.

Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries.

Antoine C, Ameye L, Paesmans M, de Azambuja E, Rozenberg S.

Maturitas. 2016 Feb;84:81-8. doi: 10.1016/j.maturitas.2015.11.010. Epub 2015 Nov 25.

PMID:
26654400
17.

Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.

Mocellin S, Pilati P, Briarava M, Nitti D.

J Natl Cancer Inst. 2015 Nov 18;108(2). pii: djv318. doi: 10.1093/jnci/djv318. Print 2016 Feb.

PMID:
26582062
18.

Lipoprotein(a)-lowering therapies: a double edged sword?

Lippi G.

Atherosclerosis. 2015 Oct;242(2):504-5. doi: 10.1016/j.atherosclerosis.2015.08.018. Epub 2015 Aug 14. No abstract available.

PMID:
26298742
19.

Postmenopausal hormone therapy and the risk of breast cancer in Norway.

Román M, Sakshaug S, Graff-Iversen S, Vangen S, Weiderpass E, Ursin G, Hofvind S.

Int J Cancer. 2016 Feb 1;138(3):584-93. doi: 10.1002/ijc.29810. Epub 2015 Sep 3.

20.

Update on management of genitourinary syndrome of menopause: A practical guide.

Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J, Rees M.

Maturitas. 2015 Nov;82(3):308-13. doi: 10.1016/j.maturitas.2015.07.020. Epub 2015 Jul 26. Review.

PMID:
26261035

Supplemental Content

Support Center